i2E

THG Energy Solutions, LLC is a provider of energy management solutions aimed at diverse sectors such as governments, healthcare, education, and retail. Founded in 2003 and headquartered in Austin, Texas, with additional offices in Tulsa and Atlanta, the company specializes in a web-based platform that facilitates utility data management and reporting. Its services include automated demand response, integrated load management, data collection and verification, and accounts payable integration. By leveraging actionable energy analytics and sustainability reporting, THG Energy Solutions helps clients achieve cost savings and resource conservation while mitigating risks. The company is committed to delivering tailored energy management strategies that align with the interests of its clients, supported by a team with expertise in energy marketing, engineering, and data management. THG Energy Solutions maintains a strategic alliance with Energy Hippo, Inc.

Simergent, LLC is a manufacturer of automated peritoneal dialysis devices, established in 2014 and headquartered in Oklahoma City, Oklahoma, with an additional presence in Chicago, Illinois. The company focuses on developing affordable home dialysis solutions for both developed and emerging markets. Its innovative device is designed to be cost-effective and user-friendly, featuring a disposable tubing set that operates independently to troubleshoot issues. This enables patients to maintain a normal lifestyle and engage socially with family and friends while undergoing treatment at home, thereby enhancing their quality of life.

Founded in 2016 and based in Norman, Oklahoma, BPEndo develops a medical device designed to address the challenge of a deflating colon during colonoscopy procedures. Its insufflation retention device creates an airtight seal, enhancing endoscope maneuverability and improving the safety and efficiency of colonoscopies.

Progentec Diagnostics, Inc. is a company focused on developing innovative diagnostic tests for managing systemic lupus erythematosus (SLE). Established in 2015 and headquartered in Oklahoma City, Oklahoma, the company has created the aiSLE DX platform, which offers tools like a flare prediction score to measure disease activity in SLE patients and an early diagnostic test for lupus. Progentec integrates advanced technology and collaborates with research institutions globally, aiming to address significant unmet needs in diagnostic interventions. The company's mission centers on improving disease management and reducing disease incidence through enhanced screening and early detection.

SendaRide, Inc. is a transportation service provider focused on non-emergency medical transportation for patients, particularly the elderly and children. Founded in 2016 and headquartered in Oklahoma City, the company operates a platform that allows users to find and book both on-demand and pre-scheduled rides. SendaRide's application offers customized transportation solutions tailored to the healthcare industry, facilitating safe and reliable transport for users. Additionally, the platform includes features such as GPS monitoring and live video feeds, allowing users to track their drivers or caretakers during transit. Users can also rate their experiences, enhancing service accountability and quality.

iRecommend Software™ develops intelligent business solutions utilizing artificial intelligence (AI), machine learning, and dynamic data modeling. In a consumer-driven economy, businesses across all industries, are facing the challenge to remain relevant and provide highly personalized products and services. iRecommend's leading solution, Recommendation360™ is a recommendation engine with applications across multiple industries, including recruiting, real estate, retail/e-commerce, entertainment, travel, government, and healthcare. These industry-specific solutions enable businesses to generate hyper-personalized recommendations of products and services for their customers. Recommendation360's proprietary technology rapidly aggregates and analyzes millions of data points from the public domain to provide the right products or services to the right person at the right time. Headquartered in Tulsa, Oklahoma with offices in Oklahoma City, New York, San Francisco, London, and Dubai.

Progentec Diagnostics, Inc. is a company focused on developing innovative diagnostic tests for managing systemic lupus erythematosus (SLE). Established in 2015 and headquartered in Oklahoma City, Oklahoma, the company has created the aiSLE DX platform, which offers tools like a flare prediction score to measure disease activity in SLE patients and an early diagnostic test for lupus. Progentec integrates advanced technology and collaborates with research institutions globally, aiming to address significant unmet needs in diagnostic interventions. The company's mission centers on improving disease management and reducing disease incidence through enhanced screening and early detection.

Spiers New Technologies Inc. specializes in providing comprehensive repair, remanufacturing, refurbishing, and repurposing services for battery packs utilized in hybrid and electric vehicles. Established in 2014 and headquartered in Oklahoma City, Oklahoma, the company enables original equipment manufacturers to effectively manage the life cycle of their battery pack inventories. In addition to its core 4R services, Spiers New Technologies conducts qualitative analysis and safety assessments of removed battery packs and manages logistics, including climate-controlled storage and recycling preparation. The company also offers contract design and manufacturing services for energy storage systems applicable to various non-vehicle uses, such as stationary electricity storage, vehicle recharging stations, and solar support systems.

Synereca Pharmaceuticals, Inc. is a research-stage biopharmaceutical company focused on developing orally active drugs that enhance the effectiveness of existing antibiotics. Founded in 2009, the company is headquartered in Chapel Hill, North Carolina, with additional laboratories in Oklahoma. Synereca's research centers on compounds that increase the activity of Colistin against gram-negative bacteria while avoiding toxicity. Its portfolio includes prototypic RecA inhibitors aimed at treating various pathogenic bacteria, including E. coli, which are responsible for infections in the lungs, urinary tract, and skin, as well as other harmful pathogens. The company identifies multiple chemical subclasses of compounds that potentiate various classes of antibiotics, including polymyxins, carbapenems, aminoglycosides, and fluoroquinolones, thereby facilitating the development of more effective treatments for bacterial infections.

Exaptive is an Oklahoma City-based platform and ecosystem that enables knowledge creation from data by connecting developers, researchers, and teams through cognitive networks. The company provides tools to organize teams and communities, facilitate collaboration on data and analysis, and connect stakeholders to generate ideas and opportunities, helping organizations design data-driven applications and accelerate problem solving.

Moleculera Labs was founded by Drs. Craig Shimasaki and Madeleine Cunningham in 2011, to medically understand and clinically identify the underlying biological root of neurological, psychiatric, and behavioral disorders. Similar to the emergence of the immuno-oncology connection, epidemiological and research evidence demonstrates that a large portion of neuropsychiatric disorders are caused by an autoimmune dysfunction. The Company owns and operates a fully accredited clinical laboratory with its first revenue generating product—a blood panel called the Cunningham Panel™ that detects brain and nervous system targeted autoimmune antibodies in patients with neurologic, psychiatric, and behavioral disorders triggered by an infection. Patients are diagnosed with PANS, PANDAS, autism spectrum disorder, ADD/ADHD, bipolar disorder, anxiety disorder, Tourette’s, obsessive compulsive disorder (OCD), schizophrenia, or other neurologic and psychiatric syndromes, whereas the root may be a dysfunctional immune response. Symptoms include OCD, anxiety, depression, psychosis, motor or vocal tics, verbal and non-verbal communication difficulty, deteriorating social skills, eating disorders, academic regression, and rage. These patients are typically prescribed neuropsychiatric drugs, often resulting in little or no improvement. However, once a patient is correctly diagnosed through testing, treatment is redirected towards the immune system, neuroinflammation, and subclinical infections, resulting in remarkable recoveries, sometimes after decades of suffering. Moleculera is the sole clinical laboratory performing this panel covered by two U.S. patents. The Company has received and processed over 13,000 blood specimens ordered by over 1,700 physicians in over 50 countries, all prior to launching a sales force. The Company generated $1.1 MM in 2021 and is preparing to scale for revenue expansion with expectations of revenue ~$25 MM in 4-5 years. The company is now applying this technology to autoimmune cardiovascular disease and Long-COVID symptoms. The basic research that led to the identification of these antineuronal antibody targets was studied for over 20 years in the laboratory of Dr. Madeleine Cunningham at The University of Oklahoma Health Sciences Center, with subsequent collaboration from the Pediatric Branch of the National Institutes of Mental Health (NIMH). Scientific and clinical results have been published in multiple top-tier peer-reviewed journals. Certain infections that have been found to trigger these autoimmune antibodies include strep, Lyme, mycoplasma, Babesia, bartonella, coxsackie virus, and others. Medical journals have reported an autoimmune response to SARS-CoV-2 (COVID-19), with approximately one-third of patients experiencing some neurologic or psychiatric symptoms. The patented Cunningham Panel™ consists of five tests. Four which measure levels of autoantibodies directed against Dopamine D1 receptor, Dopamine D2L receptor, Lysoganglioside GM1, and Tubulin. A fifth test measures CaM Kinase II activation, a key enzyme involved in the production of neurotransmitters dopamine, epinephrine, and norepinephrine. Autoimmune antibodies that bind to these targets interfere with or block normal neurologic activity in the brain and nervous system. The laboratory results assist a physician in making a diagnosis and identifying the appropriate therapy. In addition to individual clinicians who order the panel, the Company has provided testing to over 80 medical institution customers. In a 2020 publication in the Journal of Neuroimmunology, the Cunningham Panel demonstrated an 88% sensitivity and 92% specificity with an accuracy of 90% correlating these autoantibody elevations and neuropsychiatric symptoms before and after treatment. The Cunningham Panel aids a clinician’s treatment decision by directing them to the underlying subclinical infections and neuroimmune dysfunction, rather than simply treating symptoms. Effective treatments typically include various anti-infectives, anti-inflammatory agents and immunomodulators. Moleculera' s Test Panel generates an average realized revenue of $900 through existing CPT codes and patient billing. The Company has generated over $10 million in cumulative revenue since opening. During the COVID-19 pandemic, revenues for 2021 were $1.1 million, all prior to adding a sales force. Approximately 10% of orders come from a growing international market, with the Company receiving orders from over 1,700 clinicians. Moleculera Labs has one of the largest IRB approved and clinically annotated serum specimen biobanks of over 13,000 specimens utilized for research and development of new products for autoimmune neuropsychiatric disorders. The Company has demonstrated its panel’s clinical utility in multiple neuropsychiatric disorders and have been able to predict treatment efficacy while working with pharmaceutical and research partners to assist in identifying novel drug targets. There is a clear unmet medical need and demand in this $23 billion dollar neuropsychiatric and behavioral disorder market. Moleculera recently in-licensed exclusive technology for multiple autoimmune antibody targets against the heart, which are implicated in a portion of multiple cardiovascular diseases such as heart failure, cardiomyopathy, atrial fibrillation, and myocarditis. With this technology along with proposed clinical studies and validation in process, the Company expects to develop and commercialize two additional panels. One panel will target various cardiovascular diseases (world-wide market of $4.9 trillion) infection-triggered autoimmunity, and another panel for diagnosing and treatment-monitoring of Long-COVID (estimated at $6.5 trillion). Our precision medicine business model is fashioned after Foundation Medicine and Genomic Health, whose precision medicine companies were acquired by Roche in 2018 for $5.3 billion, and Exact Sciences in 2019 for $2.8 billion, respectively. Moleculera Labs is led by Dr. Craig Shimasaki, a serial entrepreneur with over 35 years of biotechnology experience, who began his career at Genentech. He co-founded multiple companies, participated in taking several companies public into the U.S. and the Canadian stock exchange, led five products through the FDA diagnostic approval process, and has directed two CLIA labs, raising over $30 million for these companies. Dr. Madeleine Cunningham, Chief Scientific Officer, is an internationally recognized leader in infection-induced autoimmune neuropsychiatric disorders and is a tenured professor at the University of Oklahoma with over 40 years of research and over 130 authored publications in leading scientific and medical journals. Dr. James Appleman is VP of R&D and Clinical Development and has 30+ years’ experience in building successful diagnostic and therapeutic companies from inception through successful exits, including a $230M exit to Roche. Mr. Fred Hiller is CFO and brings 45+ years’ experience in corporate finance and accounting. He began his career at Touche Ross & Co. in 1962, serving as controller at Elgin National and Columbia Pictures, and CFO at Wilkinson Sword. He has been a financial consultant to numerous companies including two biotechnology companies and one that was publicly traded.

Associated Material Processing, LLC is a manufacturer based in Stillwater, Oklahoma, specializing in chemical removal polymeric adsorbents for water purification. Founded in 2011, the company produces proprietary products such as ERAsE 35, a granular mesh adsorbent suitable for cleaning drinking water, groundwater, wastewater, and industrial treatments, and ERAsE 50, a free-flowing powder designed for filtration applications. The company addresses the critical issue of arsenic contamination, particularly in semiconductor manufacturing and processed foods, by offering low-cost media that effectively removes hazardous chemicals from various waste streams. This innovative approach enables manufacturers to provide purified water, contributing to the growing need for effective water treatment solutions worldwide.

Synereca Pharmaceuticals, Inc. is a research-stage biopharmaceutical company focused on developing orally active drugs that enhance the effectiveness of existing antibiotics. Founded in 2009, the company is headquartered in Chapel Hill, North Carolina, with additional laboratories in Oklahoma. Synereca's research centers on compounds that increase the activity of Colistin against gram-negative bacteria while avoiding toxicity. Its portfolio includes prototypic RecA inhibitors aimed at treating various pathogenic bacteria, including E. coli, which are responsible for infections in the lungs, urinary tract, and skin, as well as other harmful pathogens. The company identifies multiple chemical subclasses of compounds that potentiate various classes of antibiotics, including polymyxins, carbapenems, aminoglycosides, and fluoroquinolones, thereby facilitating the development of more effective treatments for bacterial infections.

Roll-2-Roll Technologies LLC is a start-up based in Stillwater, Oklahoma, that specializes in the development of electro-mechanical devices for roll-to-roll manufacturing applications. Incorporated in 2013, the company originated as a spin-off from Oklahoma State University and focuses on creating a lateral guide system that employs advanced sensor technology and algorithms. This innovative device aims to enhance manufacturing efficiency by minimizing downtime and reducing material waste. Roll-2-Roll Technologies offers a comprehensive range of products, including sensors, controllers, actuators, and other devices designed to improve web guiding and inspection processes, facilitating the easy integration of new technologies for manufacturers.

Well Checked Systems International, LLC, known as WellChecked, specializes in remote monitoring and reporting services for oil and gas well sites. Established in 2012 and headquartered in Tulsa, Oklahoma, the company provides a comprehensive unified monitoring platform that enhances the safety, security, and efficiency of well site operations. Its offerings include motion sensing, gate activity monitoring, tank level alerts, and cloud-based video surveillance with data storage and retrieval capabilities. The platform allows users to define guard patrols and monitor equipment power and motor proximity remotely. By leveraging advanced internet-based software, WellChecked helps clients reduce monitoring costs and personnel needs while minimizing the risk of equipment damage and loss.

Otologic Pharmaceutics is a biopharmaceutical company dedicated to developing novel treatments for acute noise-induced hearing loss. Its lead product, HPN1010, is an oral medication designed to prevent permanent hearing disorders.

4DSales is a company based in Tulsa, Oklahoma, that specializes in developing a tablet-based mobile sales application designed for sales professionals. This application enables users to effectively showcase products through live action videos, photos, and PDFs of specifications, facilitating customer engagement. The platform is characterized by its speed and ease of organization, providing sales teams with quick access to all necessary sales content. By enhancing the overall sales performance and responsiveness during sales calls, 4DSales aims to help businesses increase their revenue and improve their sales processes.

Tetherex Pharmaceuticals, established in 2014 with headquarters in Oklahoma City, Oklahoma, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics targeting inflammation, thrombosis, and tumor metastasis. The company's primary focus is on SelK2, a humanized monoclonal antibody designed to address these severe diseases. Tetherex operates within the healthcare industry, specifically in the biotechnology sector, with an additional office in Morrisville, North Carolina.

Moleculera Labs was founded by Drs. Craig Shimasaki and Madeleine Cunningham in 2011, to medically understand and clinically identify the underlying biological root of neurological, psychiatric, and behavioral disorders. Similar to the emergence of the immuno-oncology connection, epidemiological and research evidence demonstrates that a large portion of neuropsychiatric disorders are caused by an autoimmune dysfunction. The Company owns and operates a fully accredited clinical laboratory with its first revenue generating product—a blood panel called the Cunningham Panel™ that detects brain and nervous system targeted autoimmune antibodies in patients with neurologic, psychiatric, and behavioral disorders triggered by an infection. Patients are diagnosed with PANS, PANDAS, autism spectrum disorder, ADD/ADHD, bipolar disorder, anxiety disorder, Tourette’s, obsessive compulsive disorder (OCD), schizophrenia, or other neurologic and psychiatric syndromes, whereas the root may be a dysfunctional immune response. Symptoms include OCD, anxiety, depression, psychosis, motor or vocal tics, verbal and non-verbal communication difficulty, deteriorating social skills, eating disorders, academic regression, and rage. These patients are typically prescribed neuropsychiatric drugs, often resulting in little or no improvement. However, once a patient is correctly diagnosed through testing, treatment is redirected towards the immune system, neuroinflammation, and subclinical infections, resulting in remarkable recoveries, sometimes after decades of suffering. Moleculera is the sole clinical laboratory performing this panel covered by two U.S. patents. The Company has received and processed over 13,000 blood specimens ordered by over 1,700 physicians in over 50 countries, all prior to launching a sales force. The Company generated $1.1 MM in 2021 and is preparing to scale for revenue expansion with expectations of revenue ~$25 MM in 4-5 years. The company is now applying this technology to autoimmune cardiovascular disease and Long-COVID symptoms. The basic research that led to the identification of these antineuronal antibody targets was studied for over 20 years in the laboratory of Dr. Madeleine Cunningham at The University of Oklahoma Health Sciences Center, with subsequent collaboration from the Pediatric Branch of the National Institutes of Mental Health (NIMH). Scientific and clinical results have been published in multiple top-tier peer-reviewed journals. Certain infections that have been found to trigger these autoimmune antibodies include strep, Lyme, mycoplasma, Babesia, bartonella, coxsackie virus, and others. Medical journals have reported an autoimmune response to SARS-CoV-2 (COVID-19), with approximately one-third of patients experiencing some neurologic or psychiatric symptoms. The patented Cunningham Panel™ consists of five tests. Four which measure levels of autoantibodies directed against Dopamine D1 receptor, Dopamine D2L receptor, Lysoganglioside GM1, and Tubulin. A fifth test measures CaM Kinase II activation, a key enzyme involved in the production of neurotransmitters dopamine, epinephrine, and norepinephrine. Autoimmune antibodies that bind to these targets interfere with or block normal neurologic activity in the brain and nervous system. The laboratory results assist a physician in making a diagnosis and identifying the appropriate therapy. In addition to individual clinicians who order the panel, the Company has provided testing to over 80 medical institution customers. In a 2020 publication in the Journal of Neuroimmunology, the Cunningham Panel demonstrated an 88% sensitivity and 92% specificity with an accuracy of 90% correlating these autoantibody elevations and neuropsychiatric symptoms before and after treatment. The Cunningham Panel aids a clinician’s treatment decision by directing them to the underlying subclinical infections and neuroimmune dysfunction, rather than simply treating symptoms. Effective treatments typically include various anti-infectives, anti-inflammatory agents and immunomodulators. Moleculera' s Test Panel generates an average realized revenue of $900 through existing CPT codes and patient billing. The Company has generated over $10 million in cumulative revenue since opening. During the COVID-19 pandemic, revenues for 2021 were $1.1 million, all prior to adding a sales force. Approximately 10% of orders come from a growing international market, with the Company receiving orders from over 1,700 clinicians. Moleculera Labs has one of the largest IRB approved and clinically annotated serum specimen biobanks of over 13,000 specimens utilized for research and development of new products for autoimmune neuropsychiatric disorders. The Company has demonstrated its panel’s clinical utility in multiple neuropsychiatric disorders and have been able to predict treatment efficacy while working with pharmaceutical and research partners to assist in identifying novel drug targets. There is a clear unmet medical need and demand in this $23 billion dollar neuropsychiatric and behavioral disorder market. Moleculera recently in-licensed exclusive technology for multiple autoimmune antibody targets against the heart, which are implicated in a portion of multiple cardiovascular diseases such as heart failure, cardiomyopathy, atrial fibrillation, and myocarditis. With this technology along with proposed clinical studies and validation in process, the Company expects to develop and commercialize two additional panels. One panel will target various cardiovascular diseases (world-wide market of $4.9 trillion) infection-triggered autoimmunity, and another panel for diagnosing and treatment-monitoring of Long-COVID (estimated at $6.5 trillion). Our precision medicine business model is fashioned after Foundation Medicine and Genomic Health, whose precision medicine companies were acquired by Roche in 2018 for $5.3 billion, and Exact Sciences in 2019 for $2.8 billion, respectively. Moleculera Labs is led by Dr. Craig Shimasaki, a serial entrepreneur with over 35 years of biotechnology experience, who began his career at Genentech. He co-founded multiple companies, participated in taking several companies public into the U.S. and the Canadian stock exchange, led five products through the FDA diagnostic approval process, and has directed two CLIA labs, raising over $30 million for these companies. Dr. Madeleine Cunningham, Chief Scientific Officer, is an internationally recognized leader in infection-induced autoimmune neuropsychiatric disorders and is a tenured professor at the University of Oklahoma with over 40 years of research and over 130 authored publications in leading scientific and medical journals. Dr. James Appleman is VP of R&D and Clinical Development and has 30+ years’ experience in building successful diagnostic and therapeutic companies from inception through successful exits, including a $230M exit to Roche. Mr. Fred Hiller is CFO and brings 45+ years’ experience in corporate finance and accounting. He began his career at Touche Ross & Co. in 1962, serving as controller at Elgin National and Columbia Pictures, and CFO at Wilkinson Sword. He has been a financial consultant to numerous companies including two biotechnology companies and one that was publicly traded.

Synercon Technologies, LLC is a technology company based in Tulsa, Oklahoma, specializing in extracting digital data from heavy vehicles involved in crashes. Founded in 2013, it develops innovative solutions to retrieve data from a vehicle's engine control module (ECM) in a forensically sound manner. Its key products include the Forensic Link Adapter (FLA), which downloads data from heavy vehicles, and the Smart Sensor Simulator, which allows investigators to conduct bench downloads without causing additional fault codes. Additionally, Synercon offers TruckCRYPT, a software solution that encrypts and presents extracted data to users. The company provides a range of services, including chip-level digital forensics, field data extraction, crash reconstruction, expert testimony, and electronics design. By employing a custom hardware and software approach, Synercon enhances the efficiency and reliability of forensic investigations in the heavy vehicle sector.

Drik is a laboratory testing facility located in Oklahoma City that specializes in toxicology services for pharmaceutical companies developing new drugs. Founded and led by Kumar Sripathirathan, Drik offers customized testing solutions that assist researchers in determining toxicology requirements and evaluating the safety of their drug candidates. The company conducts a variety of pre-clinical screening tests, in vitro testing, and animal studies, alongside in vivo toxicology assessments and cell-based assays that investigate disease mechanisms. Through its comprehensive testing capabilities, Drik enables pharmaceutical companies to effectively identify and address safety concerns associated with new drug development.

ICEdot, a Tulsa, Oklahoma-based developer of a crash sensor attached to the safety helmet of sportsmen. Led by Chris Zenthoefer, CEO, ICEdot has developed a crash sensor attached to the safety helmet of cyclists, skiers, snow boarders, BMX bikers and other action sport participants to detect forces consistent with head injury and notify predesignated health and geolocation information over sms/text.

Docvia is a privately held software venture that provides secure, HIPAA-compliant electronic access between established patients and their health providers. The company's software was first commercially deployed at St. John Health System in Tulsa, Oklahoma. The Docvia team is comprised of practicing physicians, software engineers and designers that work together with community leaders in order to provide safe, simple and inexpensive health access around the world.

Founded in 2018, Medefy is a Tulsa-based healthcare technology company. It offers an app that connects employers directly with their employees regarding health benefits, enabling better communication and engagement to facilitate informed healthcare decisions. The platform helps employees find better-priced, higher-quality healthcare providers locally.

Expert TA, LLC is a company that specializes in providing web-based software for partial-credit grading, specifically designed for use by professors and teaching assistants in higher education. Established in 2009 and based in Tulsa, Oklahoma, the company focuses on enhancing the educational experience by simplifying the grading process for homework in disciplines such as engineering, mathematics, physics, and chemistry. Its offerings include Homework Mode, which enables educators to create assignments and export grade information for integration with other software, and Tutorial Mode, which provides guidance akin to office hours tutoring sessions. By automating the grading of complex problems, Expert TA allows educators to devote more time to teaching and student engagement, thereby improving overall learning outcomes.

DermaMedics LLC is a pharmaceutical skin care company based in Oklahoma City, Oklahoma, that focuses on developing innovative topical therapeutics for the dermatology market. Founded in 2010, the company specializes in creating skin care products for medical professionals, including anti-aging treatments and relief products for various skin conditions such as psoriasis, acne, rosacea, and eczema. One of its key advancements is Therosol®, a unique phytochemical compound derived from natural sources like basil and nutmeg, known for its anti-inflammatory and anti-aging properties. Clinical research has demonstrated the efficacy of Therosol® in treating inflammatory skin issues and preventing radiation burns in cancer patients. DermaMedics markets its extensive range of products—including moisturizers, cleansers, serums, and creams—through retailers, aiming to provide safe and effective solutions that enhance skin health without the adverse effects associated with traditional corticosteroids and immunosuppressive treatments.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

Exerbotics, LLC is a manufacturer of advanced fitness and wellness equipment based in Tulsa, Oklahoma, founded in 2004. The company specializes in designing technology-driven devices tailored for medical, rehabilitation, senior living, and commercial fitness applications. Their product range includes machines for various muscle groups, such as chest press, shoulder press, leg press, and more, all of which are equipped to measure and record force output. This data facilitates future analysis, diagnosis, and training prescriptions. Exerbotics also provides solutions for analyzing, repairing, and backing up performance data, along with detailed reports on biometrics and workout history. By leveraging technology, Exerbotics aims to enhance healthy living and improve quality of life through its innovative fitness solutions.

CreditPoint Software, Inc. is a company that specializes in developing software solutions for commercial credit risk and collections management. Founded in 2000 and headquartered in Tulsa, Oklahoma, the firm offers a comprehensive SaaS platform designed to assist businesses of all sizes, from small and medium enterprises to Fortune 500 companies. Its software suite includes features such as online credit applications, configurable scoring models, analytics-driven monitoring, and business intelligence reporting. By enabling effective credit risk management and collection processes, CreditPoint Software aims to enhance operational efficiency, reduce errors, and provide critical insights that help businesses mitigate risk and optimize cash flow.

Lifetone Technology, Inc. is a manufacturer of bedside fire alarm and clock products designed to enhance safety for children, seniors, heavy sleepers, and individuals who are deaf or hard of hearing. The company’s flagship brand, Lifetone HL, includes innovative devices such as a bedside fire alarm that integrates a bed shaker, which emits strong vibrations to alert users in case of a fire. Founded in 2004 and based in Oklahoma City, Oklahoma, Lifetone Technology also operates additional offices in Chicago. The company markets its lifesaving products online and through various dealers across the United States. Originally established as InnovAlarm Corporation, it rebranded to Lifetone Technology in January 2008.